Stay updated on BMS-986205 Combo with Nivolumab in Melanoma Clinical Trial
Sign up to get notified when there's something new on the BMS-986205 Combo with Nivolumab in Melanoma Clinical Trial page.

Latest updates to the BMS-986205 Combo with Nivolumab in Melanoma Clinical Trial page
- CheckyesterdayNo Change Detected
- Check8 days agoNo Change Detected
- Check15 days agoChange DetectedLocations section updated with expanded list of trial sites across multiple countries and regions, and the revision changed from v3.3.2 to v3.3.3.SummaryDifference1%

- Check22 days agoNo Change Detected
- Check44 days agoChange DetectedVersion metadata updated from v3.2.0 to v3.3.2; this is a minor revision that does not affect study content, eligibility criteria, or user-facing information. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

- Check51 days agoChange DetectedThe page removed a government funding status notice about potential delays and NIH operations. This change does not affect the study details, eligibility criteria, or results on the ClinicalTrials.gov record. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.2%

- Check65 days agoChange DetectedNo meaningful changes were detected between the two screenshots. The study details page content and layout appear unchanged.SummaryDifference0.3%

- Check94 days agoChange Detected- Added a government operations notice and operating details, plus a new v3.2.0 revision. - Removed the previous v3.1.0 revision.SummaryDifference4%

- Check101 days agoChange DetectedUpdated to Revision v3.1.0 and removal of multiple drug-safety topics (Drug Safety, Counterfeit Drugs, Pharmaceutical Preparations, Substandard Drugs), indicating content pruning in the drug-safety area and a new version tag.SummaryDifference0.5%

Stay in the know with updates to BMS-986205 Combo with Nivolumab in Melanoma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the BMS-986205 Combo with Nivolumab in Melanoma Clinical Trial page.